| Susan M Wang, DO | |
|
2068 Bridgeport Ave, Milford, CT 06460-4634 | |
| (203) 701-6787 | |
| (203) 693-2955 |
| Full Name | Susan M Wang |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 22 Years |
| Location | 2068 Bridgeport Ave, Milford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598880031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 045440 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Entity Name | Paul Fischer Md P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972838480 PECOS PAC ID: 0547396756 Enrollment ID: O20100326000728 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.
BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).
About three-fourths of children who are diagnosed with autism at age 2 years appear to have the condition at age 9 years, according to a report in the June issue of Archives of General Psychiatry.
Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, recently opened a new physical therapy clinic in Grand Haven, MI.
The Perelman School of Medicine at the University of Pennsylvania has launched a new program, called AAV 3.0, to create new viral vectors to find quicker and better treatments for an array of diseases. James M. Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center, will lead an interdisciplinary team of over 30 scientists to create this new technology platform with support provided by the University of Pennsylvania Health System.
› Verified 2 days ago
| Entity Name | Connecticut Coastal Metabolism, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730702705 PECOS PAC ID: 9032535752 Enrollment ID: O20200729002887 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.
BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).
About three-fourths of children who are diagnosed with autism at age 2 years appear to have the condition at age 9 years, according to a report in the June issue of Archives of General Psychiatry.
Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, recently opened a new physical therapy clinic in Grand Haven, MI.
The Perelman School of Medicine at the University of Pennsylvania has launched a new program, called AAV 3.0, to create new viral vectors to find quicker and better treatments for an array of diseases. James M. Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center, will lead an interdisciplinary team of over 30 scientists to create this new technology platform with support provided by the University of Pennsylvania Health System.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan M Wang, DO 2068 Bridgeport Ave, Milford, CT 06460-4634 Ph: (203) 701-6787 | Susan M Wang, DO 2068 Bridgeport Ave, Milford, CT 06460-4634 Ph: (203) 701-6787 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.
BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).
About three-fourths of children who are diagnosed with autism at age 2 years appear to have the condition at age 9 years, according to a report in the June issue of Archives of General Psychiatry.
Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, recently opened a new physical therapy clinic in Grand Haven, MI.
The Perelman School of Medicine at the University of Pennsylvania has launched a new program, called AAV 3.0, to create new viral vectors to find quicker and better treatments for an array of diseases. James M. Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center, will lead an interdisciplinary team of over 30 scientists to create this new technology platform with support provided by the University of Pennsylvania Health System.
› Verified 2 days ago
Christopher Edward Snyder, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 40 Commerce Park, Milford, CT 06460 Phone: 203-878-3531 Fax: 203-876-2169 | |
Dr. Ilene Linda Rosenberg, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 40 Commerce Park, Milford, CT 06460 Phone: 203-878-3531 Fax: 203-876-2169 | |
Zhao Lu, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 849 Boston Post Rd, Suite 100, Milford, CT 06460 Phone: 203-713-8122 | |
Julie Yip, DO Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 247 Broad St, Milford, CT 06460 Phone: 203-878-4312 | |
Dr. Gary Alan Spector, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 40 Commerce Park, Milford, CT 06460 Phone: 203-878-3531 Fax: 203-876-2169 | |
Dr. Clare Liguori Cherney, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 83 Point Beach Dr, Milford, CT 06460 Phone: 203-645-6090 Fax: 203-283-1518 | |
Muziana S Quadir, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 174 Cherry St, Milford, CT 06460 Phone: 203-877-6000 Fax: 203-877-6003 |